Search and filter stories that passed editorial review. Evidence strength, regulatory status, and guideline position are shown separately and are never inferred from one another.
In the randomized, double-blind, placebo-controlled INDIGO trial, vorasidenib significantly delayed disease progression (by blinded independent review) and delayed the time to the next anticancer intervention, compared with placebo, in a…
Afamitresgene autoleucel is an engineered T-cell therapy — reportedly the first engineered cell therapy approved for a solid tumor in the United States — that received accelerated approval based on…